CORPORATEDIGESTIIPartICRAINDUSTRYWATCHSERIESPage214ALEMBICLIMITEDStockChartvaluedofRs.100investedinSensexandCompanyFinancialIndicatorsSector:ValueManufacturingMarketcap:808(Rsmn)Turnover:4739(Rsmn)TotalReturns(%)21.8TotalAssets:3909(Rsmn)ROCE(%)21.7InterimResultsFaceValue10.0MarketPrice11252WkH/L145/60.25BkClsdate30/6/2001P/Eratio3.4FinancialHighlightsListings:NSE,BSE,RegionalFY2002FY2001QTR4QTR4%ChangeNetSalesRsmn1250.51129.910.7OtherIncomeRsmn16.215.825.3TotalExpensesRsmn1001.0920.983.7NetProfitRsmn81.881.50.37(InRsmillion)(In%)(InRs)YEAROP.INCPATTOT.DEBTNWROCERONWOPMNPMEPSCEPSDPSSHARES(in000)20026,247235######32.5#4.5721520014,2763012,0001,26721.726.615.17.141.859.63.5721520003,5142851,37299826.432.317.78.139.554.33.5721519993,3651661,35276722.424.7154.9246.7437.130.172119982,807741,29957918.713.412.12.7128.9249.524576ShareHoldingasof14/06/2000CapitalHistoryDateDetailPaidupcapital(inRsmillion)08/1999:ConversionoffacevaluetoRs1072.1604/1998:PreferentialIssue72.1610/1996:Rightsissue57.3012/1995:Equitysharecapital(Rs.100)41.18COMPANYPROFILECOMPANYPROFILECOMPANYPROFILECOMPANYPROFILECOMPANYPROFILEIncorporation:::::1907Registered/CorporateOffice:AlembicRoad,Vadodara-390003LastAnnualClosing:December2001MainBusiness:PharmaceuticalsCompanySecretary:R.M.KapadiaMajorSubsidiaries:AlembicExportsLimitedAuditors:K.S.Aiyar&Co.Bankers:::::ABN-AMROBankBankofBarodaICICIBankLimitedIndianBankINGBankPunjabNationalBankUnionBankofIndiaUTIBankVijayaBankVysyaBankDirectors:::::ChirayuR.AminMalikaC.AminDr.BabubhaiRPatelDr.MohanlalV.PatelHasmukhlalB.PatelRanjitbhaiPatelDr.ChunibhaiPatelRamanlalM.KapadiaPranavN.ParikhPromoters6%FIs8%ForeignHoldings8%Public26%CorporateBodies52%AlembicLimited#Asthe2002figuresarefromsummarisedresults,thesedetailsarenotavailableTHEINDIANPHARMACEUTICALINDUSTRYPage215PRODUCTANDTECHNOLOGYPRODUCTANDTECHNOLOGYPRODUCTANDTECHNOLOGYPRODUCTANDTECHNOLOGYPRODUCTANDTECHNOLOGYALEMBICLIMITEDBackgroundAlembicLimited(Alembic),theflagshipcompanyoftheAlembicgroup,wasincorporatedin1907asAlembicChemicalWorksLimitedbytheAminfamilyformanufactureofpharmaceuticalproducts.In1970,thecompanycommencedproductionoftwoantibiotics(streptomycinanderythromycin)andgraduallyexpandeditsmanufacturingactivitiestootherbulkdrugs.Alembiccommencedmanufacturingofformulationsin1989-90andenteredtheveterinaryandanimalhealthbusinessin1986-87.InCY2000,DarshakLimited,agroupcompanyengagedinmanufacturingofbulkchemicalswasmergedwithAlembic.Thecompanyiscurrentlyengagedinthemanufactureofbulkintermediates,bulkdrugsandformulationsanditsmanufacturingfacilitiesarelocatedatVadodaradistrictandPanchmahaldistrictinGujarat.OperationsThecompanyhastwodivisions-pharmaceuticalsandveterinary.Pharmaceuticalsaccountedfor95%ofthecompany’ssalesinCY2000withtheanimalhealthcarebusinessaccountingfortherest.Inthedomesticretailformulationsmarket,Alembicranks18th,withamarketshareofabout1.8%inCY2001.Inthepharmaceuticalsbusiness,thecompanyhasawell-diversifiedproductportfoliowithapresenceinthefollowingsegments:antibiotics,respiratory,nutritionalsupplements,cardiovascular,non-steroidalanti-inflammatorydrugs(NSAIDs),psychotrophsandanti-ulcerants.SomeofitsleadingbrandsincludeAlthrocin,Azithral,Nimegesic,Wikoryl,andGlycodinamongothers.Penicillinanditsderivatives,cephalosporins,erythromycinarethemajorbulkdrugsmanufacturedbythecompany.FinancialsInCY2000...
